A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Pharmacy"
DOI: 10.1007/s11096-017-0429-3
Abstract: Background Infusion-related reactions (IRRs) are a major adverse event of rituximab. Objective To develop a prediction model for IRRs to rituximab among patients with B cell non- Hodgkin’s lymphomas (B-NHL). Setting A 1000-bed university hospital… read more here.
Keywords: irrs rituximab; rituximab; infusion related; prediction model ... See more keywords
Risk factors for infusion-related reactions following Ocrelizumab infusion in a community setting: Development of an electronic medical record-based explanatory model.
Sign Up to like & getrecommendations! Published in 2020 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2020.102700
Abstract: BACKGROUND In 2017, ocrelizumab became the first FDA approved disease modifying therapy (DMT) for primary progressive multiple sclerosis (MS). Although effective, adverse infusion-related reactions (IRR), such as erythema, pruritus, hives, and throat irritation, were frequently… read more here.
Keywords: explanatory model; development; infusion related; related reactions ... See more keywords
Mismatched donor cell infusion-related syndrome following microtransplant in patients with acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000002611
Abstract: Abstract Background: Immunotherapies such as adoptive immune cell infusion and immune-modulating agents are widely used for cancer treatment, and the concomitant symptoms, including cytokine release syndrome (CRS) or immune-related adverse events (irAEs), are frequently reported.… read more here.
Keywords: cell; gpbmc infusion; infusion related; leukemia ... See more keywords
Hematopoietic cell infusion‐related adverse events in pediatric/small recipients in a prospective/multicenter study
Sign Up to like & getrecommendations! Published in 2020 at "Transfusion"
DOI: 10.1111/trf.15786
Abstract: Hematopoietic cell infusion‐related adverse events (HCI‐AEs) in hematopoietic stem cell transplantations (HSCTs) have been largely attributed to toxicity of dimethyl sulfoxide (DMSO) for cryopreservation, but HSC products also contain various cells and plasma components. Our… read more here.
Keywords: adverse events; infusion related; hematopoietic cell; related adverse ... See more keywords
Comparison of cryoprotectants in hematopoietic cell infusion–related adverse events
Sign Up to like & getrecommendations! Published in 2022 at "Transfusion"
DOI: 10.1111/trf.16877
Abstract: The standard cryoprotectant for human cellular products is dimethyl sulfoxide (DMSO), which is associated with hematopoietic cell infusion‐related adverse events (HCI‐AEs) in hematopoietic stem cell transplantation including peripheral blood stem cell (PBSC) transplantation (PBSCT). DMSO… read more here.
Keywords: cell; infusion related; related adverse; hematopoietic cell ... See more keywords
The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms21197213
Abstract: Fabry disease (FD) is an X-linked lysosomal disorder caused by mutations in GLA gene resulting in lack of or faulty α-galactosidase A (α-GalA) enzyme. Enzyme replacement therapy (ERT) with recombinant human α-GalA enzyme (agalsidase) is… read more here.
Keywords: mast; fabry disease; infusion related; mast cell ... See more keywords